LIVZON PHARMA (01513): Abnormal Fluctuations in A-Share Trading; No Major Matters That Should Be Disclosed but Have Not Been Disclosed

LIVZON PHARMA (01513) announced that the closing price deviation of the company's A-shares (securities abbreviation: Livzon Pharmaceutical Group Inc., securities code: 000513) accumulated to 20.82% over three consecutive trading days on September 24, September 28, and September 29, 2026. According to the relevant regulations of the Shenzhen Stock Exchange, this constitutes an abnormal fluctuation in stock trading. In response to the abnormal fluctuation in the company's stock trading, the company has verified the relevant matters and hereby explains the circumstances that may affect the abnormal fluctuation in the company's stock trading as follows: 1. There is no information previously disclosed by the company that needs to be corrected or supplemented; 2. Explanation of recent media reports: The company has not found any undisclosed material information in recent public media reports that may or has already had a significant impact on the company's stock trading price. 3. The company's recent operating conditions are normal, and there have been no major changes in the internal and external operating environment. 4. The company, its controlling shareholder, and actual controller do not have any major matters concerning the company that should be disclosed but have not been disclosed, nor are there any major matters in the planning stage. 5. The company's controlling shareholder and actual controller did not buy or sell the company's shares during the period of abnormal fluctuation in the company's stock trading. The board of directors of the company confirms that the company currently has no matters that should be disclosed but have not been disclosed pursuant to the relevant provisions such as the Rules Governing the Listing of Stocks on the Shenzhen Stock Exchange, or any planning, negotiations, intentions, agreements, etc. related to such matters; the board of directors has also not learned of any information that should be disclosed but has not been disclosed pursuant to the relevant provisions such as the Rules Governing the Listing of Stocks on the Shenzhen Stock Exchange and that has a significant impact on the trading price of the company's stocks and their derivatives; and there is no information previously disclosed by the company that needs to be corrected or supplemented.